ESR1 and neoplasm: In breast cancer, RUNX3 serves as a frequently inactivated or downregulated tumor suppressor that inhibits the proliferative and transformative potential of estrogen receptor α (ERα)-dependent cells, such as the MCF-7 cell line [36].